Determination of capecitabine and its metabolites in plasma of Egyptian colorectal cancer patients / Sara Mohamed Elsayed Shams Eldin ; Supervised Sahar Abdelmaksoud , Rasha Hanafi , Salem Eid
Material type: TextLanguage: English Publication details: Cairo : Sara Mohamed Elsayed Shams Eldin , 2015Description: 71 Leaves : charts ; 30cmSubject(s): Dissertation note: Thesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceulical Chemistry Summary: Colorectal cancer (CRC) is a type of cancer that is constantly increasing in incidence worldwide in addition to the national level. It has variable signs and symptoms starting from change in bowel habit to nausea and vomiting. Chemotherapeutic agents are often preseribed in CRC disease such as capecitabine (CCB) and 5-fluorouracil (FU). CCB is the prodrag of FU in oral dosage form, which makes it preferable by physicians, since no hospitalization is needed for drug administrationItem type | Current library | Home library | Call number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|
Thesis | قاعة الثقاقات الاجنبية - الدور الثالث | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.34.M.Sc.2015.Sa.D (Browse shelf(Opens below)) | Not for loan | 01010110072352000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceulical Chemistry
Colorectal cancer (CRC) is a type of cancer that is constantly increasing in incidence worldwide in addition to the national level. It has variable signs and symptoms starting from change in bowel habit to nausea and vomiting. Chemotherapeutic agents are often preseribed in CRC disease such as capecitabine (CCB) and 5-fluorouracil (FU). CCB is the prodrag of FU in oral dosage form, which makes it preferable by physicians, since no hospitalization is needed for drug administration
There are no comments on this title.